614 related items for PubMed ID: 22337241
1. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S.
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[Abstract] [Full Text] [Related]
2. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
[Abstract] [Full Text] [Related]
3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
Pediatrics; 2004 Dec 17; 114(6):e689-93. PubMed ID: 15545617
[Abstract] [Full Text] [Related]
4. [Kawasaki disease: what you need to know].
Bajolle F, Laux D.
Arch Pediatr; 2012 Nov 17; 19(11):1264-8. PubMed ID: 22921712
[Abstract] [Full Text] [Related]
5. Infliximab treatment for refractory Kawasaki syndrome.
Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, Balfour I, Shen CA, Michel ED, Shulman ST, Melish ME.
J Pediatr; 2005 May 17; 146(5):662-7. PubMed ID: 15870671
[Abstract] [Full Text] [Related]
6. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
J Med Assoc Thai; 2002 Nov 17; 85 Suppl 4():S1121-6. PubMed ID: 12549785
[Abstract] [Full Text] [Related]
7. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 17; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
8. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
J Med Assoc Thai; 2003 Aug 17; 86 Suppl 3():S656-60. PubMed ID: 14700163
[Abstract] [Full Text] [Related]
9. Infliximab as a novel therapy for refractory Kawasaki disease.
Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
J Rheumatol; 2004 Apr 17; 31(4):808-10. PubMed ID: 15088313
[Abstract] [Full Text] [Related]
10. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T, Takatsuki S, Kobayashi T.
Nihon Rinsho; 2014 Sep 17; 72(9):1641-9. PubMed ID: 25518416
[Abstract] [Full Text] [Related]
11. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
J Pediatr; 2011 Apr 17; 158(4):644-649.e1. PubMed ID: 21129756
[Abstract] [Full Text] [Related]
12. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T.
Pediatr Res; 2009 Jun 17; 65(6):696-701. PubMed ID: 19430379
[Abstract] [Full Text] [Related]
13. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange.
Fujimaru T, Ito S, Masuda H, Oana S, Kamei K, Ishiguro A, Kato H, Abe J.
Cytokine; 2014 Dec 17; 70(2):156-60. PubMed ID: 25082649
[Abstract] [Full Text] [Related]
14. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC, Song Y, Bujold M, Shimizu C, Kanegaye JT, Tremoulet AH, Franco A.
Clin Exp Immunol; 2013 Dec 17; 174(3):337-44. PubMed ID: 23901839
[Abstract] [Full Text] [Related]
15. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar 17; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
16. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL, Zhao SL.
Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
[Abstract] [Full Text] [Related]
17. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
[Abstract] [Full Text] [Related]
18. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.
Lee TJ, Kim KH, Chun JK, Kim DS.
Yonsei Med J; 2008 Oct 31; 49(5):714-8. PubMed ID: 18972590
[Abstract] [Full Text] [Related]
19. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
J Pediatr; 2008 Dec 31; 153(6):833-8. PubMed ID: 18672254
[Abstract] [Full Text] [Related]
20. Corticosteroid treatment of refractory Kawasaki disease.
Lang BA, Yeung RS, Oen KG, Malleson PN, Huber AM, Riley M, Ebbeson R, Ramsey SE, Laxer RM, Silverman ED, McCrindle BW, Ratnapalan S, Feldman BM.
J Rheumatol; 2006 Apr 31; 33(4):803-9. PubMed ID: 16583481
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
